Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $13
花旗集团维持对Summit Therapeutics的买入，将目标股价上调至13美元
Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from $7 to $13.
花旗集团分析师伊加尔·诺霍莫维茨维持Summit Therapeutics（纳斯达克股票代码：SMMT）的买入并将目标股价从7美元上调至13美元